The funds are part of the government’s $5 billion Project NextGen initiative to enable the rapid development of longer-lasting COVID-19 vaccines, a new antibody therapy and technologies to advance vaccine manufacturing processes, HHS said Tuesday.
ICON Government and Public Health Solutions, Pharm-Olam, Technical Resources Intl and Rho Federal Systems will collectively receive $1 billion to conduct clinical trials for new vaccines in partnership with the Biomedical Advanced Research and Development Authority.
Regeneron Pharmaceuticals will secure $326 million to create a next-generation monoclonal antibody therapy for COVID-19 prevention.
HHS will allocate $100 million to Global Health Investment Corp, a non-profit organization that invests in new technologies to accelerate responses to diseases and $10 million to Johnson & Johnson Innovation.
Radiance Technologies has elevated Darien Hammett to chief operating officer, placing him in charge of daily operations and execution across the company.…
latter’sRocket Lab announced Tuesday it has completed the acquisition of Mynaric, a laser-optical communications terminal provider, in a $155.3 million…
GreyNoise Intelligence has launched a command-and-control detection capability designed to give federal agencies earlier visibility into compromised infrastructure. GreyNoise’s new…
Textron Aviation Defense has been awarded a five-year, $150 million contract to provide sustaining engineering and program management, or SEPM, services…
